Search Results - "BEDOSSA, PIERRE"

Pathology of non‐alcoholic fatty liver disease by Bedossa, Pierre

“…Non‐alcoholic fatty liver disease (NAFLD) covers a spectrum of lesions ranging from steatosis (Non‐alcoholic Fatty Liver or NAFL) to a complex pattern with…”
Get full text

Diagnosis of non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis: Why liver biopsy is essential by Bedossa, Pierre

“…The pattern of non‐alcoholic fatty liver disease is complex with an association of several lesions, each of them related to different pathophysiological…”
Get full text

Reversibility of hepatitis B virus cirrhosis after therapy: who and why? by Bedossa, Pierre

“…The end point of liver fibrosis in almost all chronic liver diseases including HBV chronic hepatitis is cirrhosis. Progression to cirrhosis is associated with…”
Get full text

Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease by Bedossa, Pierre, Patel, Keyur

“…Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of histopathologic features, ranging from isolated hepatic steatosis, to steatohepatitis with…”
Get full text

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease by Bedossa, Pierre

“…Biopsy is still the gold standard for the diagnosis of nonalcoholic steatohepatitis but the definition may vary among pathologists, a drawback especially in…”
Get full text

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement by Eslam, Mohammed, Newsome, Philip N., Sarin, Shiv K., Anstee, Quentin M., Targher, Giovanni, Romero-Gomez, Manuel, Zelber-Sagi, Shira, Wai-Sun Wong, Vincent, Dufour, Jean-François, Schattenberg, Jörn M., Kawaguchi, Takumi, Arrese, Marco, Valenti, Luca, Shiha, Gamal, Tiribelli, Claudio, Yki-Järvinen, Hannele, Fan, Jian-Gao, Grønbæk, Henning, Yilmaz, Yusuf, Cortez-Pinto, Helena, Oliveira, Claudia P., Bedossa, Pierre, Adams, Leon A., Zheng, Ming-Hua, Fouad, Yasser, Chan, Wah-Kheong, Mendez-Sanchez, Nahum, Ahn, Sang Hoon, Castera, Laurent, Bugianesi, Elisabetta, Ratziu, Vlad, George, Jacob

“…The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic…”
Get full text

Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients by Bedossa, Pierre, Poitou, Christine, Veyrie, Nicolas, Bouillot, Jean-Luc, Basdevant, Arnaud, Paradis, Valerie, Tordjman, Joan, Clement, Karine

“…Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and being overweight is a significant risk factor. The aim was to build an algorithm along with a…”
Get full text

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease by Kumar, Divya P., Caffrey, Rebecca, Marioneaux, Jonathon, Santhekadur, Prasanna K., Bhat, Madhavi, Alonso, Cristina, Koduru, Srinivas V., Philip, Binu, Jain, Mukul R., Giri, Suresh R., Bedossa, Pierre, Sanyal, Arun J.

“…Insulin resistance and hepatic lipid accumulation constitute the metabolic underpinning of nonalcoholic steatohepatitis (NASH). We tested the hypothesis that…”
Get full text

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH by Francque, Sven M, Bedossa, Pierre, Ratziu, Vlad, Anstee, Quentin M, Bugianesi, Elisabetta, Sanyal, Arun J, Loomba, Rohit, Harrison, Stephen A, Balabanska, Rozalina, Mateva, Lyudmila, Lanthier, Nicolas, Alkhouri, Naim, Moreno, Christophe, Schattenberg, Jörn M, Stefanova-Petrova, Diana, Vonghia, Luisa, Rouzier, Régine, Guillaume, Maeva, Hodge, Alexander, Romero-Gómez, Manuel, Huot-Marchand, Philippe, Baudin, Martine, Richard, Marie-Paule, Abitbol, Jean-Louis, Broqua, Pierre, Junien, Jean-Louis, Abdelmalek, Manal F

“…Lanifibranor is a pan–peroxisome proliferator–activated receptor agonist that modulates metabolic and inflammatory pathways. In this 24-week, phase 2b,…”
Get full text

Liver Histology and Clinical Trials for Nonalcoholic Steatohepatitis-Perspectives From 2 Pathologists by Kleiner, David E, Bedossa, Pierre

Get full text

Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion by Poté, Nicolas, Cauchy, François, Albuquerque, Miguel, Voitot, Hélène, Belghiti, Jacques, Castera, Laurent, Puy, Hervé, Bedossa, Pierre, Paradis, Valérie

“…Background & Aims Prothrombin induced by vitamin K absence-II (PIVKA-II) is a diagnostic and surveillance marker for HCC mainly used in Asia, and has also been…”
Get full text

A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer by Asgharpour, Amon, Cazanave, Sophie C, Pacana, Tommy, Seneshaw, Mulugeta, Vincent, Robert, Banini, Bubu A, Kumar, Divya Prasanna, Daita, Kalyani, Min, Hae-Ki, Mirshahi, Faridoddin, Bedossa, Pierre, Sun, Xiaochen, Hoshida, Yujin, Koduru, Srinivas V, Contaifer, Daniel, Warncke, Urszula Osinska, Wijesinghe, Dayanjan S, Sanyal, Arun J

“…Graphical abstract…”
Get full text

Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis by Govaere, Olivier, Cockell, Simon, Tiniakos, Dina, Queen, Rachel, Younes, Ramy, Vacca, Michele, Alexander, Leigh, Ravaioli, Federico, Palmer, Jeremy, Petta, Salvatore, Boursier, Jerome, Rosso, Chiara, Johnson, Katherine, Wonders, Kristy, Day, Christopher P, Ekstedt, Mattias, Orešič, Matej, Darlay, Rebecca, Cordell, Heather J, Marra, Fabio, Vidal-Puig, Antonio, Bedossa, Pierre, Schattenberg, Jörn M, Clément, Karine, Allison, Michael, Bugianesi, Elisabetta, Ratziu, Vlad, Daly, Ann K, Anstee, Quentin M

“…The mechanisms that drive nonalcoholic fatty liver disease (NAFLD) remain incompletely understood. This large multicenter study characterized the…”
Get more information

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis by Karlas, Thomas, Petroff, David, Sasso, Magali, Fan, Jian-Gao, Mi, Yu-Qiang, de Lédinghen, Victor, Kumar, Manoj, Lupsor-Platon, Monica, Han, Kwang-Hyub, Cardoso, Ana C, Ferraioli, Giovanna, Chan, Wah-Kheong, Wong, Vincent Wai-Sun, Myers, Robert P, Chayama, Kazuaki, Friedrich-Rust, Mireen, Beaugrand, Michel, Shen, Feng, Hiriart, Jean-Baptiste, Sarin, Shiv K, Badea, Radu, Jung, Kyu Sik, Marcellin, Patrick, Filice, Carlo, Mahadeva, Sanjiv, Wong, Grace Lai-Hung, Crotty, Pam, Masaki, Keiichi, Bojunga, Joerg, Bedossa, Pierre, Keim, Volker, Wiegand, Johannes

“…Graphical abstract…”
Get full text

Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease by Musolino, Vincenzo, Gliozzi, Micaela, Scarano, Federica, Bosco, Francesca, Scicchitano, Miriam, Nucera, Saverio, Carresi, Cristina, Ruga, Stefano, Zito, Maria Caterina, Maiuolo, Jessica, Macrì, Roberta, Amodio, Nicola, Juli, Giada, Tassone, Pierfrancesco, Mollace, Rocco, Caffrey, Rebecca, Marioneaux, Jonathon, Walker, Ross, Ehrlich, James, Palma, Ernesto, Muscoli, Carolina, Bedossa, Pierre, Salvemini, Daniela, Mollace, Vincenzo, Sanyal, Arun J.

“…There is a need for continued drug development for nonalcoholic steatohepatitis (NASH). Bergamot is a plant whose fruit juice is enriched with flavonoids and…”
Get full text

Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study) by Degos, Francoise, Perez, Paul, Roche, Bruno, Mahmoudi, Amel, Asselineau, Julien, Voitot, Hélène, Bedossa, Pierre

“…Background & Aims The diagnostic accuracy of non-invasive liver fibrosis tests that may replace liver biopsy in patients with chronic hepatitis remains…”
Get full text

Obesity and Fatty Pancreatic Infiltration Are Risk Factors for Pancreatic Precancerous Lesions (PanIN) by Rebours, Vinciane, Gaujoux, Sébastien, d'Assignies, Gaspard, Sauvanet, Alain, Ruszniewski, Philippe, Lévy, Philippe, Paradis, Valérie, Bedossa, Pierre, Couvelard, Anne

“…The roles of intravisceral and subcutaneous fat are unknown, and the prevalence of precancerous lesions in obese patients was never evaluated. This study aims…”
Get full text

A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis by Bissonnette, Julien, Altamirano, José, Devue, Cécile, Roux, Olivier, Payancé, Audrey, Lebrec, Didier, Bedossa, Pierre, Valla, Dominique, Durand, François, Ait‐Oufella, Hafid, Sancho‐Bru, Pau, Caballeria, Joan, Ginès, Pere, Boulanger, Chantal M., Bataller, Ramon, Rautou, Pierre‐Emmanuel

“…The diagnosis of alcoholic hepatitis (AH) often requires a transjugular liver biopsy (TJLB), a procedure that is not always readily accessible. We analyzed…”
Get full text

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science by Siddiqui, Mohammad Shadab, Harrison, Stephen A., Abdelmalek, Manal F., Anstee, Quentin M., Bedossa, Pierre, Castera, Laurent, Dimick‐Santos, Lara, Friedman, Scott L., Greene, Katherine, Kleiner, David E., Megnien, Sophie, Neuschwander‐Tetri, Brent A., Ratziu, Vlad, Schabel, Elmer, Miller, Veronica, Sanyal, Arun J.

“…Nonalcoholic steatohepatitis (NASH) is an important cause of liver‐related morbidity and mortality. There are no approved therapies, and the results of…”
Get full text

Sampling variability of liver fibrosis in chronic hepatitis C by Bedossa, Pierre, Dargère, Delphine, Paradis, Valerie

“…Fibrosis is a common endpoint of clinical trials in chronic hepatitis C, and liver biopsy remains the gold standard for fibrosis evaluation. However,…”
Get full text